The G protein-coupled receptor GPR30 inhibits proliferation of estrogen receptor-positive breast cancer cells

Cancer Research

Volumn 70, Issue 3, 2010, Pages 1184-1194

  Ariazi, Eric A ^a   Brailoiu, Eugen ^a   Yerrum, Smitha ^a   Shupp, Heather A ^a   Slifker, Michael J ^a   Cunliffe, Heather E ^b   Black, Michael A ^c   Donato, Anne L ^a   Arterburn, Jeffrey B ^d   Oprea, Tudor I ^e   Prossnitz, Eric R ^e   Dun, Nae J ^a   Jordan, V Craig ^a,f  

^a TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b TRANSLATIONAL GENOMICS RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF OTAGO   (New Zealand)

^d NEW MEXICO STATE UNIVERSITY   (United States)

^e UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

^f GEORGETOWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 HYDROXYTAMOXIFEN; CALCIUM; DIETHYLSTILBESTROL; ESTROGEN RECEPTOR; ESTROGEN RECEPTOR ALPHA; G PROTEIN COUPLED RECEPTOR; G PROTEIN COUPLED RECEPTOR 30; INOSITOL TRISPHOSPHATE; PROTEIN P21; PROTEIN P53; RYANODINE RECEPTOR; SMALL INTERFERING RNA;

ARTICLE; BREAST CANCER; CALCIUM MOBILIZATION; CANCER CELL; CANCER GROWTH; CELL PROLIFERATION; CELL STRAIN MCF 7; DOWN REGULATION; ESTROGEN ACTIVITY; GENE EXPRESSION; HUMAN; HUMAN CELL; PRIORITY JOURNAL;

BREAST NEOPLASMS; CALCIUM; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLOPENTANES; DIETHYLSTILBESTROL; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; ESTROGENS; FEMALE; FLOW CYTOMETRY; G1 PHASE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOBLOTTING; QUINOLINES; RECEPTORS, G-PROTEIN-COUPLED; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 76249115409     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-09-3068     Document Type: Article

References (40)

1. Prossnitz ER, Arterburn JB, Smith HO, Oprea TI, Sklar LA, Hathaway HJ. Estrogen signaling through the transmembrane G protein-coupled receptor GPR30. Annu Rev Physiol 2008;70:165-90.
2. Prossnitz ER, Barton M. Signaling, physiological functions and clinical relevance of the G protein-coupled estrogen receptor GPER. Prostaglandins Other Lipid Mediat 2009;89:89-97.
3. Smith HO, Leslie KK, Singh M, et al. GPR30: a novel indicator of poor survival for endometrial carcinoma. Am J Obstet Gynecol 2007;196: 386.e1-9; discussion 386.e9-11.
4. Smith HO, Arias-Pulido H, Kuo DY, et al. GPR30 predicts poor survival for ovarian cancer. Gynecol Oncol 2009;114:465-71.
5. Filardo EJ, Graeber CT, Quinn JA, et al. Distribution of GPR30, a seven membrane-spanning estrogen receptor, in primary breast cancer and its association with clinicopathologic determinants of tumor progression. Clin Cancer Res 2006;12:6359-66.
6. Kuo WH, Chang LY, Liu DL, et al. The interactions between GPR30 and the major biomarkers in infiltrating ductal carcinoma of the breast in an Asian population. Taiwan J Obstet Gynecol 2007;46:135-45.
7. Vivacqua A, Bonofiglio D, Albanito L, et al. 17β-Estradiol, genistein, and 4-hydroxytamoxifen induce the proliferation of thyroid cancer cells through the G protein-coupled receptor GPR30. Mol Pharmacol 2006;70:1414-23.
8. Vivacqua A, Bonofiglio D, Recchia AG, et al. The G protein-coupled receptor GPR30 mediates the proliferative effects induced by 17β-estradiol and hydroxytamoxifen in endometrial cancer cells. Mol Endocrinol 2006;20:631-46.
9. Albanito L, Madeo A, Lappano R, et al. G protein-coupled receptor 30 (GPR30) mediates gene expression changes and growth response to 17β-estradiol and selective GPR30 ligand G-1 in ovarian cancer cells. Cancer Res 2007;67:1859-66.
10. Albanito L, Sisci D, Aquila S, et al. Epidermal growth factor induces G protein-coupled receptor 30 expression in estrogen receptor-negative breast cancer cells. Endocrinology 2008;149:3799-808.
11. Ahola TM, Manninen T, Alkio N, Ylikomi T. G protein-coupled receptor 30 is critical for a progestin-induced growth inhibition in MCF-7 breast cancer cells. Endocrinology 2002;143:3376-84.
12. Thomas P, Pang Y, Filardo EJ, Dong J. Identity of an estrogen membrane receptor coupled to a G protein in human breast cancer cells. Endocrinology 2005;146:624-32.
13. Filardo EJ, Quinn JA, Bland KI, Frackelton AR, Jr. Estrogen-induced activation of Erk-1 and Erk-2 requires the G protein-coupled receptor homolog, GPR30, and occurs via trans-activation of the epidermal growth factor receptor through release of HB-EGF. Mol Endocrinol 2000;14:1649-60.
14. Filardo EJ, Quinn JA, Frackelton AR, Jr., Bland KI. Estrogen action via the G protein-coupled receptor, GPR30: stimulation of adenylyl cyclase and cAMP-mediated attenuation of the epidermal growth factor receptor-to-MAPK signaling axis. Mol Endocrinol 2002;16:70-84.
15. Bologa CG, Revankar CM, Young SM, et al. Virtual and biomolecular screening converge on a selective agonist for GPR30. Nat Chem Biol 2006;2:207-12.
16. Dennis MK, Burai R, Ramesh C, et al. In vivo effects of a GPR30 antagonist. Nat Chem Biol 2009;5:421-7.
17. Blasko E, Haskell CA, Leung S, et al. Beneficial role of the GPR30 agonist G-1 in an animal model of multiple sclerosis. J Neuroimmunol 2009;214:67-77.
18. Lin BC, Suzawa M, Blind RD, et al. Stimulating the GPR30 estrogen receptor with a novel tamoxifen analogue activates SF-1 and promotes endometrial cell proliferation. Cancer Res 2009;69:5415-23.
19. van de Vijver MJ, He YD, van't Veer LJ, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002; 347:1999-2009.
20. Barrett T, Suzek TO, Troup DB, et al. NCBI GEO: mining millions of expression profiles-database and tools. Nucleic Acids Res 2005;33: D562-6.
21. Gentleman RC, Carey VJ, Bates DM, et al. Bioconductor: open software development for computational biology and bioinformatics. Genome Biol 2004;5:R80.
22. Jiang SY, Wolf DM, Yingling JM, Chang C, Jordan VC. An estrogen receptor positive MCF-7 clone that is resistant to antiestrogens and estradiol. Mol Cell Endocrinol 1992;90:77-86.
23. Ariazi EA, Kraus RJ, Farrell ML, Jordan VC, Mertz JE. Estrogen-related receptor α1 transcriptional activities are regulated in part via the ErbB2/HER2 signaling pathway. Mol Cancer Res 2007;5:71-85.
24. Lyng MB, Laenkholm AV, Pallisgaard N, Ditzel HJ. Identification of genes for normalization of real-time RT-PCR data in breast carcinomas. BMC Cancer 2008;8:20.
25. Brailoiu E, Churamani D, Cai X, et al. Essential requirement for twopore channel 1 in NAADP-mediated calcium signaling. J Cell Biol 2009;186:201-9.
26. Pink JJ, Jordan VC. Models of estrogen receptor regulation by estrogens and antiestrogens in breast cancer cell lines. Cancer Res 1996; 56:2321-30.
27. Liu H, Lee E-S, Gajdos C, et al. Apoptotic action of 17β-estradiol in raloxifene-resistant MCF-7 cells in vitro and in vivo. J Natl Cancer Inst 2003;95:1586-97.
28. 2+ signaling and control of growth and proliferation. Biol Cell 2004;96: 55-68.
29. Doisneau-Sixou SF, Sergio CM, Carroll JS, Hui R, Musgrove EA, Sutherland RL. Estrogen and antiestrogen regulation of cell cycle progression in breast cancer cells. Endocr Relat Cancer 2003;10: 179-86.
30. Guo Y, Yang K, Harwalkar J, et al. Phosphorylation of cyclin D1 at Thr 286 during S phase leads to its proteasomal degradation and allows efficient DNA synthesis. Oncogene 2005;24:2599-612.
31. Pines J, Hunter T. Isolation of a human cyclin cDNA: evidence for cyclin mRNA and protein regulation in the cell cycle and for interaction with p34cdc2. Cell 1989;58:833-46.
32. Pandey DP, Lappano R, Albanito L, Madeo A, Maggiolini M, Picard D. Estrogenic GPR30 signaling induces proliferation and migration of breast cancer cells through CTGF. EMBO J 2009;28:523-32.
33. 2+ transfer in the control of apoptosis. Oncogene 2008;27:6407-18.
34. Lee WJ, Robinson JA, Holman NA, McCall MN, Roberts-Thomson SJ, Monteith GR. Antisense-mediated inhibition of the plasma membrane calcium-ATPase suppresses proliferation of MCF-7 cells. J Biol Chem 2005;280:27076-84.
35. Olofsson MH, Havelka AM, Brnjic S, Shoshan MC, Linder S. Charting calcium-regulated apoptosis pathways using chemical biology: role of calmodulin kinase II. BMC Chem Biol 2008;8:2.
36. Qin C, Nguyen T, Stewart J, Samudio I, Burghardt R, Safe S. Estrogen up-regulation of p53 gene expression in MCF-7 breast cancer cells is mediated by calmodulin kinase IV-dependent activation of a nuclear factor κB/CCAAT-binding transcription factor-1 complex. Mol Endocrinol 2002;16:1793-809.
37. Ariazi EA, Jordan VC. Estrogen receptors as therapeutic targets in breast cancer. In: Ottow E, Weinmann H, editors. Nuclear receptors as drug targets. Mörlenbach: Wiley-VCH; 2008, p. 127-99.
38. Martensson UE, Salehi SA, Windahl S, et al. Deletion of the G protein-coupled receptor 30 impairs glucose tolerance, reduces bone growth, increases blood pressure, and eliminates estradiol-stimulated insulin release in female mice. Endocrinology 2009; 150:687-98.
39. Chagin AS, Savendahl L. GPR30 estrogen receptor expression in the growth plate declines as puberty progresses. J Clin Endocrinol Metab 2007;92:4873-7.
40. Wang C, Dehghani B, Li Y, et al. Membrane estrogen receptor regulates experimental autoimmune encephalomyelitis through up-regulation of programmed death 1. J Immunol 2009;182:3294-303.